Lymphoma
Conditions
Brief summary
This study is to evaluate the incidence of interstitial pneumonia in lymphoma patients treated with liposomal doxorubucin. The treatment response and other adverse events will also be studied.
Interventions
DRUGliposomal doxorubicin
intravenous liposomal doxorubicin
Sponsors
Ruijin Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Inclusion criteria
* histologically confirmed lymphoma * 18-80 years * ECOG\<= 2 * newly diagnosed lymphoma * liposomal doxorubicin is planned in the treatment * normal lung function * no history or malignancy * informed consented
Exclusion criteria
* history of malignancy, now in the treatment * pregnant * serious infection * other uncontrollable conditions judged by the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the incidence of interstitial pneumonia | up to one month after completion of study treatment | interstitial pneumonia is defined as positive CT scan with or without positive respiratory symptoms |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall response rate | 21 days after completion of study treatment | percentage of participants with overall response was determined on the basis of investigator assessments according to 2014 Lugano criteria |
| adverse events | up to 30 days after completion of study treatment | number of participants with treatment-related adverse events mainly include liposomal related AEs, eg cardiotoxicity and the incidence of hand-foot syndrome |
Countries
China
Contacts
Primary ContactWL Z
Outcome results
None listed